The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Bushueva O.O.

Privolzhsky Research Medical University;
City Hospital N 33

Antipenko E.A.

Privolzhsky Research Medical University

Update on the etiology and pathogenesis of muscle dystonia

Authors:

Bushueva O.O., Antipenko E.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(4): 127‑133

DOI: 10.17116/jnevro2021121041127

Read: 4581 times

Download PDF (RU)
Contact the author
Table of contents

UPDATE ON THE ETIOLOGY AND PATHOGENESIS OF MUSCLE DYSTONIA
UPDATE ON THE ETIOLOGY AND PATHOGENESIS OF MUSCLE DYSTONIA

To cite this article:

Bushueva OO, Antipenko EA. Update on the etiology and pathogenesis of muscle dystonia. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(4):127‑133. (In Russ.)
https://doi.org/10.17116/jnevro2021121041127

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Muscle dystonia is one of the most common extrapyramidal diseases and is the third most common after essential tremor and Parkinson’s disease. The introduction of diagnostic methods expanded the understanding of the genetic basis of muscle dystonia and neurophysiological mechanisms of dystonic phenomena. However, the questions of the etiology and pathogenesis of dystonia still remain the subject of close interest of researchers. The review provides up-to-date information about the etiology and pathogenesis of muscle dystonia. Recent changes in the genetic nomenclature of dystonia are described. Modern ideas about the pathogenetic significance of such mechanisms as abnormalities of neural inhibition, disturbances of sensorimotor integration, and abnormalities of neural plasticity are considered. Recent research data support the concept of systemic sensorimotor disintegration, including not only basal ganglia dysfunction, but also motor network disorders involving the cerebellum, cortex, midbrain, thalamus and other areas.

Keywords:

muscular dystonia
genetics of muscular dystonia
pathogenesis of dystonia
neurophysiology of dystonia

Authors:

Bushueva O.O.

Privolzhsky Research Medical University;
City Hospital N 33

Antipenko E.A.

Privolzhsky Research Medical University

Received:

18.06.2020

Accepted:

15.07.2020

Close metadata

References:

  1. Albanese A, Bhatia K, Bressman SB, et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord. 2013;28(7):863–873.  https://doi.org/10.1002/mds.25475
  2. Epidemiological Study of Dystonia in Europe Collaborative Group. A prevalence study of primary dystonia in eight European countries. J Neurol. 2000;247:787–792.  https://doi.org/10.1007/s004150070094
  3. Steeves TD, Day L, Dykeman J, et al. The prevalence of primary dystonia: a systematic review and meta-analysis. Mov Disord. 2012;27(14):1789–1796. https://doi.org/10.1002/mds.25244
  4. Müller J, Kiechl S, Wenning GK, et al. The prevalence of primary dystonia in the general community. Neurology Sep. 2002;59(6):941–943.  https://doi.org/10.1212/01.WNL.0000026474.12594.0D
  5. Fahn S, Marsden CD, Calne DB. Classification and investigation of dystonia. In: Marsden CD, Fahn S, eds. Movement disorders. 2nd ed. London: Butterworths; 1987.
  6. Albanese A, Di Giovanni M, Lalli S. Dystonia: diagnosis and management. Eur J Neurol. 2019;26(1):5–17.  https://doi.org/10.1111/ene.13762
  7. Suvorova VA, Antipenko EA. Non-motor symptoms by focal muscular dystonia. Nevrologicheskiy Zhurnal = Neurological Journal. 2018;23(4):190–194. (In Russ.).
  8. Lohmann K, Klein C. Update on the Genetics of Dystonia. Curr Neurol Neurosci Rep. 2017;17(3):26.  https://doi.org/10.1007/s11910-017-0735-0
  9. Jinnah HA, Hess EJ. Evolving concepts in the pathogenesis of dystonia. Parkinsonism Relat Disord. 2018;46(Suppl 1):62–65.  https://doi.org/10.1016/j.parkreldis.2017.08.001
  10. Marras C, Lang A, van de Warrenburg BP, et al. Nomenclature of genetic movement disorders: Recommendations of the international Parkinson and movement disorder society task force. Mov Disord. 2016;31(4):436–457.  https://doi.org/10.1002/mds.26527
  11. Timerbaeva SL, Illarioshkin SN, Abramycheva NYu, Rebrova OYu. Molekulyarno-geneticheskoe issledovanie fokal’noi/segmentarnoi pervichnoi distonii v Rossii. Soobshchenie II: analiz assotsiatsii s genom DRD5. Meditsinskaya genetika. 2012;(10):30–35. (In Russ.).
  12. Jinnah HA, Sun YV. Dystonia genes and their biological pathways. Neurobiol Dis. 2019;129:159–168.  https://doi.org/10.1016/j.nbd.2019.05.014
  13. Suspitsyn EN, Tyurin VI, Imyanitov EN, Sokolenko AP. Whole exome sequencing: principles and diagnostic capabilities. Pediatrician (St Petersburg). 2016;7(4):142–146. (In Russ.). https://doi.org/10.17816/PED74142-146
  14. Karimi M, Moerlein SM, Videen TO, et al. Decreased striatal dopamine receptor binding in primary focal dystonia: a D2 or D3 defect? Mov Disord. 2011;26(1):100–106.  https://doi.org/10.1002/mds.23401
  15. Simonyan K, Berman BD, Herscovitch P, Hallett M. Abnormal striatal dopaminergic neurotransmission during rest and task production in spasmodic dysphonia. J Neurosci. 2013;33(37):14705–14714. https://doi.org/10.1523/JNEUROSCI.0407-13.2013
  16. Kurian MA, Gissen P, Smith M, et al. The monoamine neurotransmitter disorders: an expanding range of neurological syndromes. Lancet Neurol. 2011;10(8):721–733.  https://doi.org/10.1016/S1474-4422(11)70141-7
  17. Szigetvari PD, Muruganandam G, Kallio JP, et al. The quaternary structure of human tyrosine hydroxylase: effects of dystonia-associated missense variants on oligomeric state and enzyme activity. J Neurochem. 2019;148(2):291–306.  https://doi.org/10.1111/jnc.14624
  18. Wijemanne S, Jankovic J. Dopa-responsive dystonia—clinical and genetic heterogeneity. Nat Rev Neurol. 2015;11:414–424.  https://doi.org/10.1038/nrneurol.2015.86
  19. Friedman J. Sepiapterin Reductase Deficiency. 2015 Jul 1. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2021. Accessed Feb 23, 2021. https://www.ncbi.nlm.nih.gov/books/NBK304122/
  20. Hanihara T, Inoue K, Kawanishi C, et al. 6-Pyruvoyl-tetrahydropterin synthase deficiency with generalized dystonia and diurnal fluctuation of symptoms: a clinical and molecular study. Mov Disord. 1997;12(3):408–411.  https://doi.org/10.1002/mds.870120321
  21. Rilstone JJ, Alkhater RA, Minassian BA. Brain dopamine-serotonin vesicular transport disease and its treatment. N Engl J Med. 2013;368:543–550.  https://doi.org/10.1056/NEJMoa1207281
  22. Benecke R, Strümper P, Weiss H. Electron transfer complex I defect in idiopathic dystonia. Ann Neurol. 1992;32(5):683–686.  https://doi.org/10.1002/ana.410320512
  23. Reichmann H, Naumann M, Hauck S, Janetzky B. Respiratory chain and mitochondrial deoxyribonucleic acid in blood cells from patients with focal and generalized dystonia. Mov Disord. 1994;9(6):597–600.  https://doi.org/10.1002/mds.870090603
  24. Schapira AH, Warner T, Gash MT, et al. Complex I function in familial and sporadic dystonia. Ann Neurol. 1997;41(4):556–559.  https://doi.org/10.1002/ana.410410421
  25. Tabrizi SJ, Cooper JM, Schapira AH. Mitochondrial DNA in focal dystonia: a cybrid analysis. Ann Neurol. 1998;44(2):258–261.  https://doi.org/10.1002/ana.410440218
  26. Pearson TS, Akman C, Hinton VJ, et al. Phenotypic spectrum of glucose transporter type 1 deficiency syndrome (Glut1 DS). Curr Neurol Neurosci Rep. 2013;13(4):342.  https://doi.org/10.1007/s11910-013-0342-7
  27. Asnov AYu, Sokolov AA, Volgina SA, et al. Federal’nye klinicheskie rekomendatsii po diagnostike i lecheniyu bolezni Vil’sona-Konovalova (gepatolentikulyarnaya degeneratsiya). St. Petersburg: Litografiya SPb.; 2015. (In Russ.).
  28. Zhou B, Westaway SK, Levinson B, et al. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet. 2001;28(4):345–349.  https://doi.org/10.1038/ng572
  29. Rouault TA, Cooperman S. Brain iron metabolism. Semin Pediatr Neurol. 2006;13(3):142–148.  https://doi.org/10.1016/j.spen.2006.08.002
  30. Hayflick SJ. Unraveling the Hallervorden-Spatz syndrome: pantothenate kinase-associated neurodegeneration is the name. Curr Opin Pediatr. 2003;15(6):572–577.  https://doi.org/10.1097/00008480-200312000-00005
  31. Miyajima H, Takahashi Y, Kono S. Aceruloplasminemia, an inherited disorder of iron metabolism. Biometals. 2003;16(1):205–213.  https://doi.org/10.1023/a:1020775101654
  32. Popławska-Domaszewicz K, Florczak-Wyspiańska J, Kozubski W. Update on neurodegeneration with brain iron accumulation. Neurol Neurochir Pol. 2014;48(3):206–213.  https://doi.org/10.1016/j.pjnns.2014.05.001
  33. McNeill A, Birchall D, Hayflick SJ, et al. T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation. Neurology. 2008;70(18):1614–1619. https://doi.org/10.1212/01.wnl.0000310985.40011.d6
  34. Edvardson S, Hama H, Shaag A, et al. Mutations in the fatty acid 2-hydroxylase gene are associated with leukodystrophy with spastic paraparesis and dystonia. Am J Hum Genet. 2008;83(5):643–648.  https://doi.org/10.1016/j.ajhg.2008.10.010
  35. Kruer MC, Hayflick SJ. Update on Neurodegeneration with Brain Iron Accumulation (NBIA) [Internet]. Special to The Movement Disorder Society. August/September 2010. Accessed Feb 23, 2021. https://clck.ru/TQV8F
  36. Sonek S, Cangul H, Coryell J, et al. PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain. Nat Genet. 2006;38(7):752–754.  https://doi.org/10.1038/ng1826
  37. Ramirez A, Heimbach A, Gründemann J, et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet. 2006;38(10):1184–1191. https://doi.org/10.1038/ng1884
  38. Alazami AM, Schneider SA, Bonneau D, et al. C2orf37 mutational spectrum in Woodhouse-Sakati syndrome patients. Clin Genet. 2010;78(6):585–590.  https://doi.org/10.1111/j.1399-0004.2010.01441.x
  39. Charlesworth G, Plagnol V, Holmström KM, et al. Mutations in ANO3 cause dominant craniocervical dystonia: ion channel implicated in pathogenesis. Am J Hum Genet. 2012;91(6):1041–1050. https://doi.org/10.1016/j.ajhg.2012.10.024
  40. Groen JL, Andrade A, Ritz K, et al. CACNA1B mutation is linked to unique myoclonus-dystonia syndrome. Hum Mol Genet. 2015;24(4):987–993.  https://doi.org/10.1093/hmg/ddu513
  41. Mencacci NE, Rubio-Agusti I, Zdebik A, et al. A missense mutation in KCTD17 causes autosomal dominant myoclonus-dystonia. Am J Hum Genet. 2015;96(6):938–947.  https://doi.org/10.1016/j.ajhg.2015.04.008
  42. Larsen TA, Dunn HG, Jan JE, Calne DB. Dystonia and calcification of the basal ganglia. Neurology. 1985;35(4):533–537.  https://doi.org/10.1212/wnl.35.4.533
  43. Louis ED, Michalec M, Jiang W, et al. Elevated blood harmane (1-methyl-9H-pyrido[3,4-b]indole) concentrations in Parkinson’s disease. Neurotoxicology. 2014;40:52–56.  https://doi.org/10.1016/j.neuro.2013.11.005
  44. Louis ED, Jiang W, Gerbin M, et al. Relationship between blood harmane and harmine concentrations in familial essential tremor, sporadic essential tremor and controls. Neurotoxicology. 2010;31(6):674–679.  https://doi.org/10.1016/j.neuro.2010.08.003
  45. Louis ED, Factor-Litvak P, Michalec M, et al. Blood harmane (1-methyl-9H-pyrido[3,4-b]indole) concentration in dystonia cases vs. controls. Neurotoxicology. 2014;44:110–113.  https://doi.org/10.1016/j.neuro.2014.06.010
  46. Zoccolella S, Martino D, Defazio G, et al. Hyperhomocysteinemia in movement disorders: Current evidence and hypotheses. Curr Vasc Pharmacol. 2006;4(3):237–243.  https://doi.org/10.2174/157016106777698414
  47. Jinnah HA, Neychev V, Hess EJ. The Anatomical Basis for Dystonia: The Motor Network Model. Tremor Other Hyperkinet Mov (NY). 2017;7:506.  https://doi.org/10.7916/D8V69X3S
  48. Neychev VK, Fan X, Mitev VI, et al. The basal ganglia and cerebellum interact in the expression of dystonic movement. Brain. 2008;131(Pt 9):2499–2509. https://doi.org/10.1093/brain/awn168
  49. Rossi M, Balint B, Millar Vernetti P, et al. Genetic Dystonia-ataxia Syndromes: Clinical Spectrum, Diagnostic Approach, and Treatment Options. Mov Disord Clin Pract. 2018;5(4):373–382.  https://doi.org/10.1002/mdc3.12635
  50. Fąfara-Leś A, Kwiatkowski S, Maryńczak L, et al. Torticollis as a first sign of posterior fossa and cervical spinal cord tumors in children. Childs Nerv Syst. 2014;30(3):425–430.  https://doi.org/10.1007/s00381-013-2255-9
  51. Kumandaş S, Per H, Gümüş H, et al. Torticollis secondary to posterior fossa and cervical spinal cord tumors: report of five cases and literature review. Neurosurg Rev. 2006;29(4):333–338.  https://doi.org/10.1007/s10143-006-0034-8
  52. Gruber D, Kühn AA, Schoenecker T, et al. Pallidal and thalamic deep brain stimulation in myoclonus-dystonia. Mov Disord. 2010;25(11):1733–1743. https://doi.org/10.1002/mds.23312
  53. Li Z, Prudente CN, Stilla R, et al. Alterations of resting-state fMRI measurements in individuals with cervical dystonia. Hum Brain Mapp. 2017;38(8):4098–4108. https://doi.org/10.1002/hbm.23651
  54. Kimberley TJ, Pickett KA. Differential activation in the primary motor cortex during individual digit movement in focal hand dystonia vs. healthy. Restor Neurol Neurosci. 2012;30(3):247–254.  https://doi.org/10.3233/RNN-2012-110183
  55. Cohen LG, Hallett M. Hand cramps: clinical features and electromyographic patterns in a focal dystonia. Neurology. 1988;38:1005–1012. https://doi.org/10.1212/wnl.38.7.1005
  56. Ganos C, Ferrè ER, Marotta A, et al. Cortical inhibitory function in cervical dystonia. Clinical Neurophysiology. 2018;129(2):466–472.  https://doi.org/10.1016/j.clinph.2017.11.020
  57. Quartarone A, Bagnato S, Rizzo V, et al. Abnormal associative plasticity of the human motor cortex in writer’s cramp. Brain. 2003;126(12):2586–2596. https://doi.org/10.1093/brain/awg273
  58. Lozeron P, Poujois A, Richard A, et al. Contribution of TMS and rTMS in the Understanding of the Pathophysiology and in the Treatment of Dystonia. Front Neural Circuits. 2016;10:90.  https://doi.org/10.3389/fncir.2016.00090
  59. Patel N, Jankovic J, Hallett M. Sensory aspects of movement disorders. Lancet Neurol. 2014;13(1):100–112.  https://doi.org/10.1016/S1474-4422(13)70213-8
  60. Avanzino L, Tinazzi M, Ionta S, Fiorio M. Sensory-motor integration in focal dystonia. Neuropsychologia. 2015;79(Pt B):288-300.  https://doi.org/10.1016/j.neuropsychologia.2015.07.008
  61. Bara-Jimenez W, Catalan MJ, Hallett M, Gerloff C. Abnormal somatosensory homunculus in dystonia of the hand. Ann Neurol. 1998;44(5):828–831.  https://doi.org/10.1002/ana.410440520
  62. Anastasopoulos D, Nasios G, Psilas K, et al. What is straight ahead to a patient with torticollis? Brain. 1998;121(1):91–101.  https://doi.org/10.1093/brain/121.1.91
  63. Desrochers P, Brunfeldt A, Sidiropoulos C, Kagerer F. Sensorimotor Control in Dystonia. Brain Sci. 2019;9(4):79.  https://doi.org/10.3390/brainsci9040079
  64. Khosravani S, Buchanan J, Johnson MD, Konczak J. Effect of Neck Botulinum Neurotoxin Injection on Proprioception and Somatosensory-Motor Cortical Processing in Cervical Dystonia. Neurorehabil Neural Repair. 2020;34(4):309–320.  https://doi.org/10.1177/1545968320905799
  65. Quartarone A, Morgante F, Sant’angelo A, et al. Abnormal plasticity of sensorimotor circuits extends beyond the affected body part in focal dystonia. J Neurol Neurosurg Psychiatry. 2008;79(9):985–990.  https://doi.org/10.1136/jnnp.2007.121632
  66. Kroneberg D, Plettig P, Schneider GH, Kühn AA. Motor Cortical Plasticity Relates to Symptom Severity and Clinical Benefit From Deep Brain Stimulation in Cervical Dystonia. Neuromodulation. 2018;21(8):735–740.  https://doi.org/10.1111/ner.12690
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.